Summary The DNA stemline ploidy was measured by flow cytometry (FCM) in 129 samples from paraffinembedded primary testicular tumours (61 seminomas, 68 non-seminomas). Only one DNA stemline was found in 38 seminomas and 44 non-seminomas. Two seminomas and one non-seminoma were DNA diploid, the other tumours being non-diploid. Twenty-three seminomas and 24 non-seminomas displayed two or three DNA stemlines. The median minimal DNA index (DI) of all seminomas was significantly higher than that of all non-seminomas (1.58 vs 1.43; P: 0.008). Three seminomas removed from two monozygotic twins within I week had DIs of 1.66, 1.56 and 1.59. In this limited series there was no association between DNA ploidy of the primary tumour and the metastatic status for either seminomas or non-seminomas.
DNA flow cytometry (DNA FCM) has given clinically valuable information in several types of human solid tumours (Tribukait, 1987; Kallioniemi et al., 1987; Kaern et al., 1990) . In general, non-diploid tumours and/or those tumours with a high S-phase fraction are found to have a particularly high malignant potential. The results from DNA FCM have also contributed to the understanding of the pathogenesis, for example, of human bladder cancer (Gustafson et al., 1982; Tribukait, 1987) .
DNA FCM measurements in samples from paraffin-embedded formalin-fixed material (Hedley et al., 1983) , enable the study of even rare tumour types such as testicular cancer (Sledge et al., 1987; FossA et al., 1991) . The results have led to interesting pathogenetic considerations, but the relevance of DNA FCM in testicular cancer is still unclear.
The aim of the present study was to study the pathogenetic and clinical relevance of flow-cytometric DNA analysis in primary testicular cancer.
Patients and methods
One hundred and twenty-nine patients with histologically proven testicular cancer were studied (Table I) . Sixty-eight patients had non-seminoma, either pure (44) or combined with seminoma (24) . Sixty-one patients had pure classical seminoma. The patients were clinically staged according to the Royal Marsden Hospital Classification System (Peckham et al., 1979) . All non-seminoma patients and 48 seminoma patients had clinical stage I disease. The remaining 13 seminoma patients had clinical stage II (eight patients) or stage III (five patients).
The patients were treated at the Norwegian Radium Hospital according to previously described schedules (FossA & Thorud, 1986) . Suspensions of nuclei from the primary tumours were prepared (Hedley et al., 1983) and stained with ethidium bromide (Jacobsen et al., 1988) . A laboratory built flow cytometer was used (Steen & Lindmo, 1979) . The FCM histograms were analysed with the reference to the DNA indices (DIs) of identifiable stemlines (Hiddeman et al., 1984 Figure 1 ). Two seminomas and one non-seminoma were found to be diploid. Thirteen seminoma and 18 non-seminoma patients displayed two DNA stemlines, whereas three DNA stemlines were observed in ten seminomas and six non-seminomas (Figure 2 ).
The series contained three separate seminomas removed from monozygotic twins within 1 week (One twin with bilateral tumours, the other one with a unilateral tumour). Interestingly the three seminomas displayed similar DNA histograms with DIs of 1.66, 1.56 and 1.59 (Figure 3) .
There was no association between DNA ploidy and metastatic status in the seminomas or non-seminomas (Table III) .
Discussion
We have previously demonstrated a satisfactory correlation between the DIs derived from DNA FCM in fresh and paraffin-embedded testicular cancer tissue (Fossa et al., 1991) . The technique cannot discriminate a difference between stemlines of less than 10%. Diploid tumours should therefore be regarded as 'near-diploid', with the individual DI being 1.0±10%.
The estimation of the S phase fraction in paraffinembedded material is uncertain due to the relatively high amounts of debris in the nuclear solutions, and therefore has been omitted from the present study. In human cancer the S phase may prove to be of greater clinical significance than the DNA ploidy per se, as in patients with node-negative breast cancer (O'Reilly et al., 1990 (Tribukait et al., 1987 as expressed by the metastatic potential was, however, not associated with particularly low DIs or multiplicity of the DNA stemlines. This is in contrast to Nativ et al.'s (1989) observations on the prognostic significance of DNA ploidy, but is consistent with the work of Oosterhuis et al. (1989) and Quirke et al. (1986) . Our findings may be due to the small number of cases examined. It may also be that chromosomal changes not detectable by DNA FCM are more closely related to the stage and prognosis of the testicular germ cell tumour than DNA stemline ploidy. Bosl et al. (1989) have shown that the presence of the isochromosome il2p may be correlated to prognosis.
The present study and other work published so far on DNA FCM in germ cell tumours contribute to the understanding of the oncogenesis of this tumour. Larger studies should be done to correlate the clinical course of testicular cancer with the results of DNA FCM.
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